Université Libre de Bruxelles (ULB), Institute for Interdisciplinary Research (IRIBHM), and ULB Institute of Neuroscience (UNI), 808 Route de Lennik, 1070 Brussels, Belgium.
Department of Pathology, University of Chicago, Chicago, IL 60637, USA.
Cancer Cell. 2014 Dec 8;26(6):797-812. doi: 10.1016/j.ccell.2014.10.021.
Disrupted differentiation during development can lead to oncogenesis, but the underlying mechanisms remain poorly understood. Here we identify BCL6, a transcriptional repressor and lymphoma oncoprotein, as a pivotal factor required for neurogenesis and tumor suppression of medulloblastoma (MB). BCL6 is necessary for and capable of preventing the development of GNP-derived MB in mice, and can block the growth of human MB cells in vitro. BCL6 neurogenic and oncosuppressor effects rely on direct transcriptional repression of Gli1 and Gli2 effectors of the SHH pathway, through recruitment of BCOR corepressor and SIRT1 deacetylase. Our findings identify the BCL6/BCOR/SIRT1 complex as a potent repressor of the SHH pathway in normal and oncogenic neural development, with direct diagnostic and/or therapeutic relevance for SHH MB.
发育过程中的分化障碍可导致肿瘤发生,但潜在机制仍知之甚少。在这里,我们确定了 BCL6,一种转录抑制剂和淋巴瘤癌蛋白,是神经发生和髓母细胞瘤(MB)肿瘤抑制所必需的关键因素。BCL6 是必需的,并且能够防止小鼠中 GNP 衍生的 MB 的发展,并且可以在体外阻断人 MB 细胞的生长。BCL6 的神经发生和肿瘤抑制作用依赖于 SHH 通路的 Gli1 和 Gli2 效应物的直接转录抑制,通过募集 BCOR 核心抑制物和 SIRT1 去乙酰化酶。我们的研究结果确定了 BCL6/BCOR/SIRT1 复合物作为正常和致瘤性神经发育中 SHH 通路的有效抑制剂,对 SHH MB 具有直接的诊断和/或治疗意义。